Patent status of durysta?

Durysta is Allergan (now AbbVie)’s intracameral dexamethasone implant for glaucoma/ocular hypertension. The patent landscape for Durysta is multi‑layered and jurisdiction‑specific, covering:
- composition/structure of the dexamethasone implant (the drug plus the biodegradable polymer matrix)
- methods of use (intracameral delivery to lower intraocular pressure)
- device/formulation specifics and manufacturing

Because there are multiple patent families and continuations, plus possible term extensions in different regions, the exact expiry dates vary by country and can be affected by legal proceedings and patent term adjustments.

If you’d like, I can look up the current, jurisdiction-specific status and list the relevant patent numbers and expiry dates (e.g., US, EU, JP). Please tell me:
- which jurisdiction(s) you care about (US, Europe, other),
- and whether you want a summary now or a detailed patent-family map with legal status and expiration dates.

Note: for definitive legal status, consult a patent attorney or a dedicated patent database, since status can change with ongoing renewals, challenges, and term adjustments.